Core Viewpoint - Shanghai Pharmaceuticals' subsidiary, Shanghai First Biochemical, has received drug registration certificates for oxytocin injection and octreotide acetate injection in the Philippines, allowing them to enter the market without significant R&D costs [1] Group 1: Product Details - Oxytocin is used for induction of labor and was approved in China in 1994 [1] - Octreotide acetate is used for treating acromegaly and was approved in China in 2006, passing the consistency evaluation for generic drugs in 2022 [1] Group 2: Market Impact - The sales forecast for oxytocin in the Philippines is estimated at $970,000 in 2024 [1] - The approval of these drugs is expected to help expand the company's overseas market presence [1] Group 3: Financial Considerations - The registration costs for these drugs were approximately 50,000 yuan, with no additional R&D expenses incurred [1] - Sales may face uncertainties due to factors such as policy changes and exchange rate fluctuations [1]

Market Overview - The pharmaceutical commercial sector increased by 0.27% on August 21, with Guofang Co., Ltd. leading the gains [1] - The Shanghai Composite Index closed at 3771.1, up 0.13%, while the Shenzhen Component Index closed at 11919.76, down 0.06% [1] Stock Performance - Guofang Co., Ltd. (600538) closed at 6.41, up 1.91% with a trading volume of 315,600 shares and a transaction value of 202 million yuan [1] - Nanjing Pharmaceutical (600713) closed at 5.39, up 1.70% with a trading volume of 181,000 shares and a transaction value of 96.97 million yuan [1] - Shanghai Pharmaceuticals (601607) closed at 19.20, up 0.95% with a trading volume of 173,600 shares and a transaction value of 333 million yuan [1] - Yifeng Pharmacy (603939) closed at 24.49, up 0.91% with a trading volume of 88,100 shares and a transaction value of 215 million yuan [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 277 million yuan from institutional investors, while retail investors saw a net inflow of 293 million yuan [2] - The data indicates that institutional investors are withdrawing capital, while retail investors are increasing their investments in the sector [2] Individual Stock Capital Flow - Nanjing Pharmaceutical saw a net inflow of 16.81 million yuan from institutional investors, while retail investors had a net outflow of 4.14 million yuan [3] - Yifeng Pharmacy experienced a net inflow of 15.49 million yuan from institutional investors, with a net outflow of 23.62 million yuan from retail investors [3] - China National Pharmaceutical (600056) had a net inflow of 8.93 million yuan from institutional investors, while retail investors had a negligible net inflow of 0.12 million yuan [3]

证券时报·数据宝统计，截至今日下午13:59，上证综指3777.53点，收于年线之上，涨跌幅为0.30%，A 股总成交额为19493.27亿元。到目前为止，今日有28只A股价格突破了年线，其中乖离率较大的个股有 美好医疗、长虹美菱、康乐卫士等，乖离率分别为13.20%、3.88%、3.73%；春秋航空、青岛港、上海 医药等个股乖离率较小，刚刚站上年线。 （文章来源：证券时报网） | 证券代 | 证券简 | 今日涨跌幅 | 今日换手率 | 年线 | 最新价 | 乖离率 | | --- | --- | --- | --- | --- | --- | --- | | 码 | 称 | （%） | （%） | （元） | （元） | （%） | | 301363 | 美好医 疗 | 16.34 | 29.76 | 20.38 | 23.07 | 13.20 | | 000521 | 长虹美 菱 | 5.74 | 6.32 | 7.81 | 8.11 | 3.88 | | 833575 | 康乐卫 士 | 3.83 | 3.18 | 17.52 | 18.17 | 3.73 | | 300760 | 迈瑞医 疗 | 4. ...

Market Overview - The Shanghai Composite Index is at 3781.13 points, above the annual line, with a change of 0.40% [1] - The total trading volume of A-shares is 1,193.158 billion yuan [1] Stocks Breaking Annual Line - A total of 31 A-shares have surpassed the annual line today, with notable stocks including Meihua Medical, *ST Aowei, and Pianzaihuang, showing divergence rates of 14.13%, 2.94%, and 2.77% respectively [1] - Stocks with smaller divergence rates that have just crossed the annual line include China Wuyi, Huilun Crystal, and Zhuoshengwei [1] Top Stocks by Divergence Rate - Meihua Medical (301363) has a significant increase of 17.30% with a turnover rate of 23.04% and a divergence rate of 14.13% [1] - *ST Aowei (002231) increased by 3.12% with a turnover rate of 7.79% and a divergence rate of 2.94% [1] - Pianzaihuang (600436) rose by 3.70% with a turnover rate of 1.03% and a divergence rate of 2.77% [1] Additional Notable Stocks - Tongrentang (600085) increased by 1.93% with a divergence rate of 1.77% [1] - Maire Medical (300760) rose by 3.40% with a divergence rate of 1.53% [1] - Other stocks with minor divergence rates include Aima Technology (603529) and China Railway Construction (601186) with divergence rates of 1.06% and 0.96% respectively [1]

行业主要上市公司：国药控股(01099.HK);上海医药(601607.SH);华润医药(03320.HK);九州通(600998.SH);南京医药(600713.SH);华东医药(000963.SZ);英特集团(000411.SZ) 批发模式中第三终端受互联网医院青睐 批发模式即分销模式，是指批量将药品和医疗器械销售给直接接触消费者的最后环节，包括医疗机构、零售药店、基层医疗机构等或下游分销商。根据销售对象的不同批发模式可进一步区分为以 零售模式规模小但毛利率高 零售模式是指零售药店从医药制造企业或其他医药流通企业购进医药产品后，将其销售给个人消费者以赚取进销差价的模式。相较于批发模式，零售模式的规模更小，但毛利率更高。零售模式具 医药流通行业主要商业模式可分为三类 医药商业是医药行业的子行业之一，是专门从事医药商品经营活动的独立经济分支，主要负责药品在市场上的流通。医药流通行业主要商业模式可分为批发模式、零售模式和各类新型流通模式三 第三方医药冷链物流优势明显 "十四五"时期，药品流通行业需构建现代智慧医药供应链服务新体系，完善行业标准着重提升网络化、规模化、专业化水平使医药物流网络布局更加合理仓储运输全 ...

批发模式中第三终端受互联网医院青睐 转自：前瞻产业研究院 行业主要上市公司：国药控股(01099.HK);上海医药(601607.SH);华润医药(03320.HK);九州通 (600998.SH);南京医药(600713.SH);华东医药(000963.SZ);英特集团（维权）(000411.SZ)等 医药流通行业主要商业模式可分为三类 医药商业是医药行业的子行业之一，是专门从事医药商品经营活动的独立经济分支，主要负责药品在市 场上的流通。医药流通行业主要商业模式可分为批发模式、零售模式和各类新型流通模式三类。批发毛 利率较低其中又分为纯销、快批和调拨等;零售毛利率较高药品零售企业一般就是所谓的零售药店是直 接面对最终消费者患者的商品流通环节也是药品流通的最终环节。 批发模式即分销模式，是指批量将药品和医疗器械销售给直接接触消费者的最后环节，包括医疗机构、 零售药店、基层医疗机构等或下游分销商。根据销售对象的不同批发模式可进一步区分为以下几类：医 院直销：商业调拨、第三终端。此外由于渠道下沉、分散等特点，第三终端目前也是各互联网医药企业 积极布局的市场。 零售模式规模小但毛利率高 零售模式是指零售药店从医药 ...

Market Overview - The pharmaceutical commercial sector increased by 0.05% on August 20, with Yifeng Pharmacy leading the gains [1] - The Shanghai Composite Index closed at 3766.21, up 1.04%, while the Shenzhen Component Index closed at 11926.74, up 0.89% [1] Stock Performance - Yifeng Pharmacy (603939) closed at 24.27, up 0.87% with a trading volume of 58,700 shares and a turnover of 141 million yuan [1] - Other notable performers include: - Liuyuan Group (603368) at 18.64, up 0.76% [1] - China National Pharmaceutical Group (600511) at 30.01, up 0.60% [1] - Shanghai Pharmaceuticals (601607) at 19.02, up 0.58% [1] - Nanjing Pharmaceutical (600713) at 5.30, up 0.57% [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 377 million yuan from institutional investors, while retail investors saw a net inflow of 367 million yuan [2] - Notable capital flows include: - Yifeng Pharmacy had a net outflow of 9.79 million yuan from institutional investors [3] - Heavy Drug Holdings (000950) saw a net inflow of 7.45 million yuan from institutional investors [3] - Drug Easy Purchase (300937) had a net inflow of 3.82 million yuan from institutional investors [3]

*注：AH股是指同时在A股和港股上市的公司，溢价（A/H）越大，说明H股相比A股越便宜。 8月18日，上证指数涨0.85%，收报3728.03点，恒生指数跌0.37%，收报25176.85点。 上海医药AH溢价达62.94%，位居AH股溢价率第49位。当日收盘，上海医药A股报18.95元，涨幅 0.74%，H股报12.67港元，下跌0.39%。 资料显示，上海医药集团股份有限公司(以下简称"上海医药"或"公司")是沪港两地上市的大型医药产业 集团(港交所股票代码:02607;上交所股票代码:601607)。公司主营业务覆盖医药工业与商业,入选上证180 指数、沪深300指数成分股、摩根斯坦利中国指数(MSCI)。上海医药倡导"创新、诚信、合作、包容、 责任"的企业核心价值观,致力于持之以恒,提升民众的健康生活品质,努力打造成为受人尊敬、具有行业 美誉度的领先品牌药制造商和健康领域服务商。上海医药坚持创新发展,持续加大研发创新投入,加快创 新转型发展。 本文源自：金融界 作者：行情君 ...

董事會會議通告 上海醫藥集團股份有限公司（「本公司」）董事會（「董事會」）謹此宣佈， 董事會會議將於二零二五年八月二十八日（星期四）舉行，藉以（其中包括） 批准本公司及其附屬公司截至二零二五年六月三十日止六個月之中期業績及其 發佈。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因依賴該等內容而引致的任何損失承擔任何責任。 上海醫藥集團股份有限公司 Shanghai Pharmaceuticals Holding Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代碼：02607） 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 中國上海，二零二五年八月十八日 於本公告日期，本公司的執行董事為楊秋華先生、沈波先生、李永忠先生及董明先生； 非執行董事為張文學先生；以及獨立非執行董事為顧朝陽先生、霍文遜先生、王忠先生 及萬鈞女士。 * 僅供識別 ...

Core Viewpoint - Recently, Shanghai Pharmaceuticals (601607) established a new subsidiary, Up Pharmaceutical Holdings (Yongzhou) Co., Ltd., with a registered capital of 20 million yuan, indicating an expansion in its operational capabilities in the pharmaceutical sector [1] Company Summary - The new company is co-owned by Shanghai Pharmaceuticals' subsidiary, Up Pharmaceutical Holdings (Hunan) Co., Ltd., and Yongzhou Big Health Industry Co., Ltd., reflecting a strategic partnership in the health industry [1] - The business scope of the new entity includes drug wholesale, sales of Class II and III radiation devices, operation of Class III medical devices, general equipment repair, and professional design services, showcasing a diverse range of services [1]